Hospital & Healthcare Services · Founded 2003 · www.kaya.in · BSE 539276 · NSE KAYA · ISIN INE587G01015
No Notes Added Yet
Business
Kaya Ltd. is an Indian company primarily engaged in providing specialized skincare, haircare, and body contouring services through its chain of clinics. It offers a range of aesthetic dermatological solutions, anti-aging treatments, laser hair reduction, hair transplant, acne treatments, and various beauty therapies. Kaya operates on a service-led business model, charging customers for consultations, procedures, and treatment packages. It also generates revenue from the sale of its proprietary skincare and haircare products.
Revenue Mix
Kaya Ltd. primarily operates in two segments: Services and Products. While specific detailed revenue contribution percentages are not consistently broken down publicly, the majority of its revenue typically comes from its service offerings (aesthetic treatments, consultations, procedures) delivered through its clinics. Product sales, including its Kaya-branded dermatological products, contribute a smaller but significant portion of overall revenue.
Industry
Kaya operates in the fragmented but growing Indian aesthetic dermatology and healthcare services industry. This industry includes large chains, independent dermatologist clinics, multi-specialty hospitals with dermatology departments, and smaller beauty parlors offering some aesthetic services. Kaya is positioned as a premium player focusing on science-backed solutions and medical expertise. It competes with other organized chains like VLCC, Oliva Skin & Hair Clinic, and numerous local and regional players, differentiating itself through its doctor-led approach and standardized protocols.
MOAT
Kaya's competitive advantages include:
Brand Recognition: Established brand name in the Indian aesthetic dermatology space, associated with quality and medical expertise.
Clinic Network & Scale: A significant footprint of clinics across major Indian cities provides accessibility and leverages brand presence.
Medical Professionals: Emphasizes doctor-led treatments and standardized protocols, building trust and perceived quality.
Proprietary Products: Development and sale of its own skincare and haircare products complement its service offerings and build brand loyalty.
Growth Drivers
Rising Disposable Incomes: Increasing affluence among the Indian middle and upper classes leads to higher discretionary spending on appearance and wellness.
Growing Awareness & Acceptance: Increasing media exposure and social influence are reducing the stigma associated with cosmetic procedures and driving demand.
Expansion into Tier 2/3 Cities: Untapped potential in smaller cities presents opportunities for clinic expansion and market penetration.
Technological Advancements: Adoption of new, effective, and less invasive aesthetic technologies can attract more customers.
Focus on Anti-Aging: The aging population and desire for youthful appearance continue to fuel demand for anti-aging treatments.
Risks
Intense Competition: Highly fragmented market with numerous local and national players, leading to pricing pressures.
Discretionary Spending Nature: Demand for services is sensitive to economic downturns as they are often considered non-essential.
Reputational Risk: Any adverse incident or customer dissatisfaction can severely impact brand trust and business.
Talent Retention: High attrition rates for skilled dermatologists and therapists can affect service quality and operational costs.
Regulatory Changes: Potential for increased regulation in the aesthetic medicine sector regarding procedures, equipment, and product claims.
Management & Ownership
Kaya Ltd. was initially conceptualized and promoted by the Marico Group (led by Harsh Mariwala), a prominent Indian FMCG conglomerate. While Kaya was subsequently demerged, the promoter group (Mariwala family entities) continues to hold a significant stake, indicating their long-term commitment. Management consists of experienced professionals in the retail and healthcare sectors, focusing on strategic expansion and operational efficiency. The ownership structure includes the promoter group, institutional investors, and public shareholders.
Outlook
Kaya Ltd. is positioned in a growing market driven by increasing consumer awareness and spending on aesthetics. Its established brand and clinic network provide a solid foundation for growth, potentially benefiting from market expansion and premiumization trends. However, the company faces significant challenges from intense competition, the discretionary nature of its services making it susceptible to economic cycles, and the need to continuously innovate and maintain high service standards. Sustained growth will depend on effective market penetration, efficient operational management, and the ability to differentiate its offerings in a crowded market.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 54 | 52 | 52 | 53 | 58 | 55 | 53 | 54 | 60 | 56 |
| Other Income | 1 | 2 | 11 | 1 | 1 | 4 | 1 | 4 | 2 | 2 |
| Total Income | 55 | 54 | 62 | 53 | 59 | 59 | 53 | 58 | 62 | 58 |
| Total Expenditure | 44 | 117 | 46 | 47 | 53 | 53 | 49 | 57 | 71 | 68 |
| Operating Profit | 12 | -64 | 16 | 6 | 6 | 6 | 4 | 1 | -10 | -11 |
| Interest | 7 | 7 | 7 | 8 | 8 | 8 | 8 | 9 | 9 | 9 |
| Depreciation | 9 | 9 | 9 | 9 | 10 | 9 | 10 | 11 | 12 | 12 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5 | 4 |
| Profit Before Tax | -4 | -79 | 0 | -11 | -11 | -11 | -14 | -19 | -36 | -28 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | -4 | -79 | 0 | -11 | -11 | -11 | -14 | -19 | -36 | -28 |
| Adjustments | -5 | -20 | 103 | -5 | 15 | 4 | 0 | 0 | -0 | 0 |
| Profit After Adjustments | -9 | -99 | 103 | -16 | 4 | -7 | -14 | -19 | -36 | -28 |
| Adjusted Earnings Per Share | -6.9 | -75.9 | 78.6 | -12 | 2.8 | -5.4 | -10.8 | -12.4 | -23.4 | -18.3 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 370 | 409 | 400 | 421 | 393 | 275 | 324 | 377 | 205 | 217 | 222 | 223 |
| Other Income | 12 | 11 | 10 | 4 | 9 | 15 | 12 | 5 | 5 | 17 | 9 | 9 |
| Total Income | 382 | 420 | 410 | 425 | 402 | 290 | 336 | 381 | 210 | 234 | 231 | 231 |
| Total Expenditure | 352 | 425 | 398 | 406 | 338 | 248 | 297 | 363 | 174 | 198 | 232 | 245 |
| Operating Profit | 30 | -4 | 12 | 19 | 64 | 42 | 39 | 19 | 36 | 37 | -1 | -16 |
| Interest | 4 | 5 | 7 | 9 | 22 | 19 | 21 | 42 | 27 | 32 | 38 | 35 |
| Depreciation | 17 | 20 | 24 | 29 | 75 | 60 | 86 | 93 | 102 | 38 | 56 | 45 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | -1 |
| Profit Before Tax | 9 | -30 | -19 | -19 | -33 | -37 | -68 | -116 | -94 | -33 | -96 | -97 |
| Provision for Tax | 0 | -3 | -0 | -6 | 21 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 9 | -27 | -19 | -14 | -54 | -37 | -68 | -116 | -94 | -33 | -96 | -97 |
| Adjustments | -0 | -2 | -2 | -2 | -0 | -1 | -1 | -0 | -35 | 117 | 0 | 0 |
| Profit After Adjustments | 9 | -29 | -21 | -16 | -54 | -38 | -69 | -116 | -129 | 84 | -96 | -97 |
| Adjusted Earnings Per Share | 6.8 | -22.2 | -16.2 | -12.2 | -41.7 | -29.1 | -52.7 | -89.2 | -98.9 | 63.9 | -63.3 | -64.9 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 2% | -16% | -4% | -5% |
| Operating Profit CAGR | -103% | NAN% | NAN% | NAN% |
| PAT CAGR | 0% | 0% | 0% | NAN% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -33% | -5% | -8% | -10% |
| ROE Average | 0% | 0% | -53% | -35% |
| ROCE Average | -776% | -259% | -190% | -90% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 251 | 229 | 210 | 158 | 82 | 54 | -2 | -104 | -227 | -139 | -153 |
| Minority's Interest | 0 | 2 | 2 | 1 | 1 | 0 | 1 | 1 | -0 | 0 | 0 |
| Borrowings | 0 | 19 | 14 | 19 | 22 | 29 | 79 | 142 | 141 | 144 | 149 |
| Other Non-Current Liabilities | 18 | -14 | -12 | -9 | 119 | 103 | 88 | 82 | 95 | 90 | 109 |
| Total Current Liabilities | 142 | 190 | 137 | 180 | 189 | 182 | 196 | 249 | 286 | 142 | 172 |
| Total Liabilities | 412 | 425 | 351 | 349 | 413 | 368 | 361 | 370 | 296 | 237 | 278 |
| Fixed Assets | 149 | 193 | 201 | 206 | 303 | 279 | 240 | 217 | 174 | 158 | 193 |
| Other Non-Current Assets | 32 | 46 | 30 | 29 | 15 | 12 | 16 | 11 | 20 | 14 | 13 |
| Total Current Assets | 231 | 187 | 120 | 115 | 95 | 78 | 106 | 143 | 102 | 66 | 72 |
| Total Assets | 412 | 425 | 351 | 349 | 413 | 368 | 361 | 370 | 296 | 237 | 278 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 28 | 27 | 14 | 20 | 19 | 7 | 12 | 20 | 25 | 18 | 7 |
| Cash Flow from Operating Activities | 5 | -8 | -12 | 22 | 47 | 32 | 30 | 63 | 39 | 1 | 21 |
| Cash Flow from Investing Activities | -6 | -42 | 24 | -28 | -12 | 4 | -35 | -40 | -9 | 25 | -63 |
| Cash Flow from Financing Activities | -0 | 33 | -7 | 5 | -47 | -31 | 12 | -18 | -38 | -37 | 37 |
| Net Cash Inflow / Outflow | -2 | -16 | 6 | -1 | -12 | 5 | 7 | 5 | -7 | -11 | -6 |
| Closing Cash & Cash Equivalent | 28 | 14 | 20 | 19 | 7 | 12 | 20 | 25 | 18 | 7 | 1 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 6.82 | -22.23 | -16.22 | -12.22 | -41.66 | -29.1 | -52.69 | -89.15 | -98.91 | 63.89 | -63.32 |
| CEPS(Rs) | 20 | -5.54 | 4.14 | 11.74 | 16.19 | 17.4 | 13.75 | -17.58 | 6.27 | 3.26 | -26.6 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 194.12 | 174.73 | 159.66 | 119.02 | 60.61 | 41.7 | -2.17 | -81.58 | -174.93 | -106.61 | -103.8 |
| Core EBITDA Margin(%) | 4.78 | -3.87 | 0.56 | 3.56 | 14.15 | 9.8 | 8.32 | 3.73 | 15.08 | 9.04 | -4.48 |
| EBIT Margin(%) | 3.57 | -5.99 | -3.12 | -2.36 | -2.8 | -6.7 | -14.57 | -19.84 | -32.34 | -0.44 | -26.29 |
| Pre Tax Margin(%) | 2.39 | -7.29 | -4.82 | -4.59 | -8.4 | -13.61 | -20.98 | -30.86 | -45.68 | -15.36 | -43.23 |
| PAT Margin (%) | 2.39 | -6.66 | -4.72 | -3.27 | -13.76 | -13.61 | -20.98 | -30.86 | -45.68 | -15.36 | -43.23 |
| Cash Profit Margin (%) | 6.97 | -1.76 | 1.35 | 3.64 | 5.38 | 8.27 | 5.55 | -6.1 | 3.99 | 1.97 | -18.16 |
| ROA(%) | 2.24 | -6.51 | -4.87 | -3.93 | -14.21 | -9.58 | -18.64 | -31.81 | -28.17 | -12.54 | -37.37 |
| ROE(%) | 3.76 | -11.41 | -8.68 | -7.57 | -46.11 | -55.98 | -263.21 | 0 | 0 | 0 | 0 |
| ROCE(%) | 5.43 | -9.62 | -5.06 | -4.65 | -7.24 | -18.27 | -53.94 | -121.62 | 0 | 0 | -776.46 |
| Receivable days | 0.95 | 1.57 | 2.63 | 3.96 | 4.89 | 5.61 | 4.02 | 3.57 | 6.64 | 5.07 | 2.18 |
| Inventory Days | 42.64 | 45.91 | 42.46 | 37.46 | 36.76 | 42.24 | 30.75 | 27.33 | 51.68 | 45.69 | 37.64 |
| Payable days | 371.38 | 355.46 | 1585.5 | 1523.06 | 1058.8 | 1518.93 | 1829.08 | 1177.87 | 1305.49 | 763.48 | 429.39 |
| PER(x) | 126.22 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.65 | 0 |
| Price/Book(x) | 4.44 | 4.46 | 6.54 | 6.01 | 1.84 | 7.11 | -161.21 | -3.1 | -1.79 | -2.19 | -2.3 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 2.93 | 2.51 | 3.41 | 2.26 | 0.43 | 1.49 | 1.6 | 1.11 | 2.78 | 2.04 | 2.35 |
| EV/Core EBITDA(x) | 35.93 | -229.92 | 115.84 | 49.7 | 2.61 | 9.83 | 13.37 | 22.59 | 16.01 | 12.06 | -414.33 |
| Net Sales Growth(%) | 11.32 | 10.59 | -2.12 | 5.12 | -6.57 | -30.07 | 17.82 | 16.29 | -45.54 | 5.84 | 2.44 |
| EBIT Growth(%) | -62.99 | -285.89 | 48.99 | 20.42 | -10.61 | -67.36 | -156.16 | -58.39 | 11.23 | 98.55 | -5979.9 |
| PAT Growth(%) | -72.13 | -407.73 | 30.63 | 27.27 | -293.44 | 30.86 | -81.66 | -71.08 | 19.38 | 64.4 | -188.22 |
| EPS Growth(%) | 0 | -425.87 | 27.04 | 24.66 | -240.91 | 30.15 | -81.09 | -69.19 | -10.95 | 164.59 | -199.12 |
| Debt/Equity(x) | 0 | 0.13 | 0.12 | 0.22 | 0.37 | 0.66 | -30.33 | -1.33 | -0.78 | -1.03 | -1.04 |
| Current Ratio(x) | 1.62 | 0.98 | 0.87 | 0.64 | 0.5 | 0.43 | 0.54 | 0.57 | 0.36 | 0.46 | 0.42 |
| Quick Ratio(x) | 1.25 | 0.72 | 0.56 | 0.4 | 0.31 | 0.28 | 0.4 | 0.45 | 0.26 | 0.28 | 0.3 |
| Interest Cover(x) | 3.04 | -4.64 | -1.84 | -1.06 | -0.5 | -0.97 | -2.27 | -1.8 | -2.42 | -0.03 | -1.55 |
| Total Debt/Mcap(x) | 0 | 0.03 | 0.02 | 0.04 | 0.2 | 0.09 | 0.19 | 0.43 | 0.43 | 0.47 | 0.45 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 59.79 | 59.79 | 59.64 | 59.64 | 59.64 | 59.64 | 51.43 | 51.43 | 51.43 | 51.43 |
| FII | 0.74 | 1.24 | 1.27 | 1.27 | 1.5 | 0.95 | 0.63 | 0.63 | 0.68 | 0.71 |
| DII | 1.97 | 3.53 | 3.61 | 3.37 | 1.71 | 2.09 | 2.53 | 2.79 | 2.95 | 2.99 |
| Public | 37.5 | 35.43 | 35.48 | 35.72 | 37.16 | 37.32 | 45.41 | 45.15 | 44.93 | 44.88 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.78 | 0.78 | 0.78 | 0.78 | 0.78 | 0.78 | 0.78 | 0.78 | 0.78 | 0.78 |
| FII | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| DII | 0.03 | 0.05 | 0.05 | 0.04 | 0.02 | 0.03 | 0.04 | 0.04 | 0.04 | 0.05 |
| Public | 0.49 | 0.46 | 0.46 | 0.47 | 0.49 | 0.49 | 0.69 | 0.69 | 0.68 | 0.68 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.31 | 1.31 | 1.31 | 1.31 | 1.31 | 1.31 | 1.52 | 1.52 | 1.52 | 1.52 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +2% | -16% | -4% | -5% |
| Operating Profit CAGR | -103% | 0% | 0% | 0% |
| PAT CAGR | — | — | — | 0% |
| Share Price CAGR | -33% | -5% | -8% | -10% |
| ROE Average | 0% | 0% | -53% | -35% |
| ROCE Average | -776% | -259% | -190% | -90% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 59.79 | 59.79 | 59.64 | 59.64 | 59.64 | 59.64 | 51.43 | 51.43 | 51.43 | 51.43 |
| FII | 0.74 | 1.24 | 1.27 | 1.27 | 1.5 | 0.95 | 0.63 | 0.63 | 0.68 | 0.71 |
| DII | 1.97 | 3.53 | 3.61 | 3.37 | 1.71 | 2.09 | 2.53 | 2.79 | 2.95 | 2.99 |
| Public | 37.5 | 35.43 | 35.48 | 35.72 | 37.16 | 37.32 | 45.41 | 45.15 | 44.93 | 44.88 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.78 | 0.78 | 0.78 | 0.78 | 0.78 | 0.78 | 0.78 | 0.78 | 0.78 | 0.78 |
| FII | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| DII | 0.03 | 0.05 | 0.05 | 0.04 | 0.02 | 0.03 | 0.04 | 0.04 | 0.04 | 0.05 |
| Public | 0.49 | 0.46 | 0.46 | 0.47 | 0.49 | 0.49 | 0.69 | 0.69 | 0.68 | 0.68 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.31 | 1.31 | 1.31 | 1.31 | 1.31 | 1.31 | 1.52 | 1.52 | 1.52 | 1.52 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.